[Organic Synthesis Pharmaceuticals] FY2027 Full-Year Earnings Forecast Revision | Sales of 16,000 million yen

Overview of Performance

Organic Synthesis Pharmaceuticals Co., Ltd. has revised its full-year earnings forecast for FY2027, projecting sales of 16,000 million yen, operating profit of 550 million yen, ordinary income of 500 million yen, and net income attributable to owners of parent of 600 million yen. The outlook has been adjusted considering procurement trends of raw materials and geopolitical influences in the Middle East. This reflects a policy to promote flexible management strategies to respond to future business environment fluctuations.

Future Outlook and Impact on Investors

There is a possibility that geopolitical risks and rising raw material and fuel prices may affect performance, and forecasts may be revised as necessary. The specific figures for the medium-term management plan will be announced once finalized. Investors should pay attention to future risk factors and the trend of profit improvements.